OptimizeRx Corp

OptimizeRx Corp. announced the launch of its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool designed for integration into demand-side platforms (DSPs) and agency media planning platforms. NLAB leverages real-world evidence and OptimizeRx's EHR network data to enable life sciences companies and marketers to create and manage custom healthcare provider (HCP) audiences more efficiently. This new technology, available for integration from August 2026, aims to enhance audience intelligence, expand the company's infrastructure role, and generate new recurring revenue streams.

OptimizeRx Corporation held its 2026 Annual Meeting of Shareholders on June 9, 2026, where several key proposals were voted upon. Shareholders approved an amendment to increase the number of shares available for awards under the 2021 Equity Incentive Plan by 1,000,000 shares, bringing the total to 5,450,000. However, a separate amendment to adopt an evergreen provision for automatic annual increases in the Equity Plan was not approved. Additionally, shareholders elected seven directors, approved executive compensation on an advisory basis, and ratified Grant Thornton, LLP as the independent auditor for 2026.

OptimizeRx announced the departure of its Chief Commercial Officer, Theresa Greco, effective June 15, 2026. In connection with her separation, Ms. Greco will receive a severance package including 12 months of her $380,000 base salary, a $209,000 annual cash bonus, and COBRA premium reimbursements. She will also provide advisory services to the company for 12 months, during which her equity will continue to vest.

OptimizeRx Corp. announced its management will participate in two upcoming investor conferences in June 2026. The company will attend the Stifel 2026 Boston Cross Sector 1x1 Conference on June 2-3, 2026, for one-on-one meetings. Additionally, OptimizeRx will participate in William Blair & Company's 46th Annual Growth Stock Conference from June 2-4, 2026, which will include 1x1 meetings and a corporate presentation on June 3.

OptimizeRx Corp reported a narrower net loss of $0.495 million for Q1 2026, a significant improvement from $2.199 million in Q1 2025, despite a 9.5% decrease in net revenue to $19.844 million. The company's Board authorized a share repurchase program of up to $10 million and extended the maturity date of its term loan to October 2029. Net cash used in operating activities was $0.467 million, a decrease from $3.864 million provided in the prior year.

OptimizeRx Corp. secured a new $35.0 million senior secured credit facility with Fifth Third Bank, comprising a $10.0 million revolving credit facility and a $25.0 million term loan. This refinancing is expected to generate approximately $1.5 million in annual interest expense savings and replaces the existing term loan. For Q1 2026, the company reported revenue of $19.8 million, a GAAP net loss of $(0.5) million, and adjusted EBITDA of $3.3 million. OptimizeRx updated its fiscal year 2026 revenue guidance to $95-$100 million, while maintaining adjusted EBITDA guidance at $21-$25 million.

OptimizeRx Corp. reported Q1 2026 revenue of $19.8 million, a 10% decrease year-over-year. Despite the revenue decline, the company narrowed its GAAP net loss to $(0.5) million and significantly increased non-GAAP net income to $2.7 million and adjusted EBITDA to $3.3 million. OptimizeRx updated its 2026 revenue guidance to $95-$100 million, while maintaining its adjusted EBITDA guidance at $21-$25 million. The company also completed a debt refinancing, expected to save $1.5 million annually in interest, and launched efficiency initiatives projected to save $3 million annually.

OptimizeRx Corp. announced the launch of a new programmatic connection point between its proprietary EHR network and Demand-Side Platforms (DSPs). This innovation allows life sciences media buyers to activate scalable, point-of-care campaigns directly within their existing programmatic workflows, combining programmatic efficiency with precision targeting of healthcare providers in their clinical workflow. The launch also expands OptimizeRx's access to the programmatic market, which accounts for an estimated 90% of total U.S. digital display ad spend, and enables DSPs to differentiate their offerings and capture a larger share of the $19B+ pharma digital ad market.

OptimizeRx Corp announced its Annual Meeting of Shareholders for June 9, 2026, to be held virtually. Shareholders will vote on the election of seven directors, an advisory approval of executive compensation, and two amendments to the 2021 Equity Incentive Plan. The proposed amendments include increasing available shares by 1,000,000 to 5,450,000 and adopting an evergreen provision for automatic annual increases. Additionally, shareholders will ratify Grant Thornton LLP as the independent auditor for fiscal year 2026.

OptimizeRx Corp. (OPRX) has published its 2026 Environmental, Social and Governance (ESG) report, highlighting its commitment to corporate citizenship. Key developments include the appointment of Mary Varghese Presti as an independent director to the Board, bringing over 25 years of experience in healthcare and technology. The company also expanded its greenhouse gas emissions reporting to include Scope 3 supply chain emissions for the first time since 2022.